Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries o As of July 26, 2022, Pluri’s stock will trade under the symbol PLUR o The new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainability o Visit our new Company website: www.pluri-biotech.com HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harnessed for a range of fields beyond medicine, providing solutions for various areas of the life sciences. As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol “PLUR,” CUSIP number 72942G 104. Pluri’s technology will continue to fuel medical research and develop pharmaceuticals, while also being used to potentially create novel cell-based solutions for other innovative initiatives—such as food-tech, agri-tech, and biologics—either independently or through partnerships, to drive global wellbeing and sustainability. “We believe that there is tremendous need in many industries for a cell-based development platform that provides quality and precision yet is also efficient, scalable, cost effective, and consistent batch to batch. Pluri’s technology offers all these capabilities and more,” said Pluri’s CEO and President Yaky Yanay. “After nearly two decades as Pluristem, we are proud to expand as Pluri, leveraging our revolutionary technology to increase our market share across multiple verticals. Like our new logo’s dot-connecting arch suggests, it is time for Pluri to move from this single point to next generation products across a range of fields.” Pluri’s first collaboration, based on its innovative 3D cell-based technology platform, was formed in January 2022 to produce sustainable cultured food with Israeli food giant Tnuva Group. The Company intends to continue bringing technology to life, creating next-generation cell-based products that improve human wellbeing, increase environmental sustainability, and advance solutions to the challenges of the future. “Our goal is to transform cells into solutions that make the world a better place,” said Yanay. “Increasing our activity across multiple verticals means we can do even more to improve human life and contribute to a more sustainable planet. We look to solve our globe’s largest and most pressing issues starting with the smallest unit of any organism: a single cell.”